Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Amortizatization of Intangibles (2023 - 2025)

Historic Amortizatization of Intangibles for BioXcel Therapeutics (BTAI) over the last 3 years, with Q3 2025 value amounting to $82000.0.

  • BioXcel Therapeutics' Amortizatization of Intangibles rose 649.35% to $82000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $321000.0, marking a year-over-year increase of 664.45%. This contributed to the annual value of $306000.0 for FY2024, which is 625.0% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Amortizatization of Intangibles of $82000.0 as of Q3 2025, which was up 649.35% from $81000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' Amortizatization of Intangibles' 5-year high stood at $82000.0 during Q3 2025, with a 5-year trough of $70000.0 in Q1 2023.
  • In the last 3 years, BioXcel Therapeutics' Amortizatization of Intangibles had a median value of $75000.0 in 2024 and averaged $76000.0.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 416.67% in 2024, then soared by 800.0% in 2025.
  • BioXcel Therapeutics' Amortizatization of Intangibles (Quarter) stood at $74000.0 in 2023, then grew by 6.76% to $79000.0 in 2024, then grew by 3.8% to $82000.0 in 2025.
  • Its last three reported values are $82000.0 in Q3 2025, $81000.0 for Q2 2025, and $79000.0 during Q1 2025.